Ex­clu­sive: 'Faster is­n't bet­ter' — Atom­wise moves from part­ner­ships to pipeline with TYK2 drug

Atom­wise, one of the first star­tups to start pitch­ing an AI rev­o­lu­tion in drug dis­cov­ery just over a decade ago is now tak­ing a page from the tra­di­tion­al biotech play­book.

The San Fran­cis­co biotech is shift­ing its fo­cus from ink­ing hun­dreds of part­ner­ships that use its AI tech­nol­o­gy to de­vel­op­ing its own pipeline, start­ing with a TYK2 drug. Atom­wise has hired Neely Mozaf­far­i­an as its chief med­ical of­fi­cer, CEO Abra­ham Heifets told End­points News in an ex­clu­sive in­ter­view on his com­pa­ny’s fu­ture. Mozaf­far­i­an is an in­dus­try vet­er­an of Gen­tiBio, John­son & John­son, and Gilead Sci­ences.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER